Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure. / Chirinos, Julio A; Zhao, Lei; Jia, Yi; Frej, Cecilia; Adamo, Luigi; Mann, Douglas; Shewale, Swapnil V; Millar, John S; Rader, Daniel J; French, Benjamin; Brandimarto, Jeff; Margulies, Kenneth B; Parks, John S; Wang, Zhaoqing; Sieffert, Dietmar A; Fang, James; Sweitzer, Nancy; Christoffersen, Christina; Dahlbäck, Björn; Car, Bruce D; Gordon, David A; Cappola, Thomas P; Javaheri, Ali.
I: Circulation, Bind 141, Nr. 18, 2020, s. 1463–1476.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure
AU - Chirinos, Julio A
AU - Zhao, Lei
AU - Jia, Yi
AU - Frej, Cecilia
AU - Adamo, Luigi
AU - Mann, Douglas
AU - Shewale, Swapnil V
AU - Millar, John S
AU - Rader, Daniel J
AU - French, Benjamin
AU - Brandimarto, Jeff
AU - Margulies, Kenneth B
AU - Parks, John S
AU - Wang, Zhaoqing
AU - Sieffert, Dietmar A
AU - Fang, James
AU - Sweitzer, Nancy
AU - Christoffersen, Christina
AU - Dahlbäck, Björn
AU - Car, Bruce D
AU - Gordon, David A
AU - Cappola, Thomas P
AU - Javaheri, Ali
PY - 2020
Y1 - 2020
N2 - Background: Apolipoprotein M (APOM) mediates the physical interaction between high-density lipoprotein (HDL) particles and sphingosine-1-phosphate (S1P). APOM exerts anti-inflammatory and cardio-protective effects in animal models. Methods: In a subset of Penn-HF study (PHFS) participants (n=297), we measured APOM by ELISA. We also measured total S1P by liquid chromatography-mass spectrometry and isolated HDL particles to test the association between APOM and HDL-associated S1P. We confirmed the relationship between APOM and outcomes using modified aptamer-based APOM measurements, among 2,170 adults in the PHFS and 2 independent cohorts: the Washington University HF registry (n=173) and a subset of the TOPCAT trial (n=218). Finally, we examined the relationship between APOM and ~5000 other proteins (SomaScan assay) to identify biological pathways associated with APOM in HF. Results: In the PHFS, APOM was inversely associated with the risk of death (Standardized Hazard Ratio=0.56; 95%CI=0.51-0.61; P<0.0001) and the composite of death/ventricular assist device or heart transplant (Standardized HR=0.62; 95%CI=0.58-0.67; P<0.0001). This relationship was independent of HDL-C or APOA-I levels. APOM remained associated with death (HR=0.78; 0.69-0.88; P<0.0001) and the composite of death/ventricular assist device/heart transplant (HR=0.85; 95%CI=0.76-0.94; P=0.001) in models that adjusted for multiple confounders. This association was present in both HF with reduced (HFrEF) and preserved (HFpEF) ejection fraction, and was replicated in the Washington University cohort and a HFpEF-only cohort (TOPCAT). The S1P and APOM content of isolated HDL particles strongly correlated (R=0.81; P<0.0001). The top canonical pathways associated with APOM were inflammation (negative association), the coagulation system (negative association) and LXR/RXR activation (positive association). The relationship with inflammation was validated with multiple inflammatory markers measured with independent assays. Conclusions: Reduced circulating APOM is independently associated with adverse outcomes across the spectrum of human HF. Further research is needed to assess whether the APOM/S1P axis is a suitable therapeutic target in HF.
AB - Background: Apolipoprotein M (APOM) mediates the physical interaction between high-density lipoprotein (HDL) particles and sphingosine-1-phosphate (S1P). APOM exerts anti-inflammatory and cardio-protective effects in animal models. Methods: In a subset of Penn-HF study (PHFS) participants (n=297), we measured APOM by ELISA. We also measured total S1P by liquid chromatography-mass spectrometry and isolated HDL particles to test the association between APOM and HDL-associated S1P. We confirmed the relationship between APOM and outcomes using modified aptamer-based APOM measurements, among 2,170 adults in the PHFS and 2 independent cohorts: the Washington University HF registry (n=173) and a subset of the TOPCAT trial (n=218). Finally, we examined the relationship between APOM and ~5000 other proteins (SomaScan assay) to identify biological pathways associated with APOM in HF. Results: In the PHFS, APOM was inversely associated with the risk of death (Standardized Hazard Ratio=0.56; 95%CI=0.51-0.61; P<0.0001) and the composite of death/ventricular assist device or heart transplant (Standardized HR=0.62; 95%CI=0.58-0.67; P<0.0001). This relationship was independent of HDL-C or APOA-I levels. APOM remained associated with death (HR=0.78; 0.69-0.88; P<0.0001) and the composite of death/ventricular assist device/heart transplant (HR=0.85; 95%CI=0.76-0.94; P=0.001) in models that adjusted for multiple confounders. This association was present in both HF with reduced (HFrEF) and preserved (HFpEF) ejection fraction, and was replicated in the Washington University cohort and a HFpEF-only cohort (TOPCAT). The S1P and APOM content of isolated HDL particles strongly correlated (R=0.81; P<0.0001). The top canonical pathways associated with APOM were inflammation (negative association), the coagulation system (negative association) and LXR/RXR activation (positive association). The relationship with inflammation was validated with multiple inflammatory markers measured with independent assays. Conclusions: Reduced circulating APOM is independently associated with adverse outcomes across the spectrum of human HF. Further research is needed to assess whether the APOM/S1P axis is a suitable therapeutic target in HF.
U2 - 10.1161/CIRCULATIONAHA.119.045323
DO - 10.1161/CIRCULATIONAHA.119.045323
M3 - Journal article
C2 - 32237898
VL - 141
SP - 1463
EP - 1476
JO - Circulation
JF - Circulation
SN - 0009-7322
IS - 18
ER -
ID: 239256455